Sydney, June 29, 2007 (ABN Newswire) - Compumedics Limited (ASX: CMP) - Expands into Sleep Therapy - Mr David Burton, Chairman; Boardroomradio is pleased to announce that Compumedics Limited (ASX: CMP) has published an audio file. The following presentation "Expands into Sleep Therapy" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Broadcaster: Compumedics Limited (ASX: CMP)
Broadcast Title: Expands into Sleep Therapy
Broadcast Type: Audio stream
View the Audio stream for Compumedics Limited (ASX: CMP) below.
Compumedics Limited, founded in 1987, is a global leader in the design and manufacture of diagnostic technologies for sleep disorders, neurophysiology and cardiology. In 1987 Compumedics established Asia Pacific's first fully computerised sleep laboratory. Compumedics holds an 80% share of the Australian sleep-diagnostic market, and has a major and rapidly growing presence in the US, European and Asian markets for its sleep, neurological, and Doppler blood-flow diagnostic monitoring devices. Compumedics has grown to become a global medical diagnostic company with world leadership in three of the most exciting high-growth sectors and some 12,000 systems installed. Compumedics' businesses now include core and pioneering sleep-diagnostics (Sleep Division), neuro-diagnostics (Neuroscan and Neuroscience Divisions), and non-invasive blood-flow diagnostics (DWL Division). All of these fields were pioneered or discovered in the 1980s, validated in the 1990s and are only now undergoing rapid commercialisation into the rapidly expanding $1 billion plus global market.
News 
